Ardent Health (ARDT) Q2 2024 earnings summary

Executive summary

• Achieved Q2 2024 revenue of $1.47 billion, up 7.5% year-over-year, with net income attributable to the company rising 29% to $42.8 million and Adjusted EBITDA up 20% to $122 million, driven by higher patient volumes, improved reimbursement, and cost efficiencies.

• Completed IPO in July 2024, raising over $208 million in net proceeds, converting to a Delaware corporation, and strengthening liquidity and capital structure.

• Operates 30 acute care hospitals and over 200 care sites across six states, with a 6.5% increase in affiliated providers year-over-year.

• Strategic framework focuses on market share growth, operational excellence, and disciplined capital deployment, with a robust expansion pipeline and scalable growth through technology and joint ventures.

• Operations have recovered from the 2023 cybersecurity incident, though some billing delays and related expenses continue.

Financial highlights

• Q2 2024 revenue was $1.47 billion, up 7.5% year-over-year; Adjusted EBITDA reached $122 million, up from $101.9 million in Q2 2023.

• Net income attributable to the company was $42.8 million for Q2 2024, up from $33.1 million in Q2 2023.

• Adjusted EBITDAR margin before non-controlling interest was 12.7%, up from 12.0% in Q2 2023.

• Salaries and benefits were $624 million (42.4% of revenue), and supplies expense was $259 million (17.6% of revenue), both improved as a percentage of revenue year-over-year.

• Cash provided by operating activities was $120 million, up from $43 million in Q2 2023.

Outlook and guidance

• Full-year 2024 guidance: total revenue of $5.75–$5.9 billion, Adjusted EBITDA of $415–$435 million, net income of $163–$182 million, and EPS of $1.23–$1.37.

• Capital expenditures expected between $170–$185 million for 2024.

• Adjusted admissions growth forecasted at 4.0–4.5% and net patient revenue per adjusted admission growth at 2.3–4.4%.

• Guidance includes a $27 million Adjusted EBITDA impact from the Oklahoma DPP program and expects material benefit from new Medicaid programs.

• Guidance subject to uncertainties such as supplemental payment program changes, legal claims, and economic conditions.